European Journal of Pediatrics

, Volume 168, Issue 11, pp 1391–1394 | Cite as

Nonalcoholic fatty liver disease during valproate therapy

  • Alberto VerrottiEmail author
  • Giovanna Di Marco
  • Rosanna la Torre
  • Piernicola Pelliccia
  • Francesco Chiarelli
Short Report


Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight. We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment. Laboratory data revealed hyperinsulinemia with insulin resistance. After the withdrawal of VPA therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization. The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.


Valproic acid Insulin resistance Obesity Nonalcoholic fatty liver disease 


Conflict of interest

All authors have no financial relationship with any organization.


  1. 1.
    Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231PubMedCrossRefGoogle Scholar
  2. 2.
    Blackburn GL, Mun EC (2004) Effects of weight loss surgeries on liver disease. Semin Liver Dis 24:371–379PubMedCrossRefGoogle Scholar
  3. 3.
    Braillon A, Capron JP, Herve MA et al (1985) Liver in obesity. Gut 26:133–139PubMedCrossRefGoogle Scholar
  4. 4.
    Brunt EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24:3–20PubMedGoogle Scholar
  5. 5.
    Bugianesi E, McCullough AJ, Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:987–1000PubMedCrossRefGoogle Scholar
  6. 6.
    Cacciari E, Milani S, Balsamo A et al (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 29:581–593PubMedGoogle Scholar
  7. 7.
    Cutfield WS, Jefferies CA, Jackson WE et al (2003) Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children. Pediatr Diabetes 4:119–125PubMedCrossRefGoogle Scholar
  8. 8.
    Dichter MA, Brodie MJ (1996) New antiepileptic drugs. N Engl J Med 334:1583–1590PubMedCrossRefGoogle Scholar
  9. 9.
    Dinesen H, Gram L, Andersen T, Dam M (1984) Weight gain during treatment with valproate. Acta Neurol Scand 70:65–69PubMedCrossRefGoogle Scholar
  10. 10.
    Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17–26PubMedCrossRefGoogle Scholar
  11. 11.
    Farrell GC (2002) Drugs and steatohepatitis. Semin Liver Dis 22:185–194PubMedCrossRefGoogle Scholar
  12. 12.
    Grant LM, Lisker-Melman M (2004) Nonalcoholic fatty liver disease. Ann Hepatol 3:93–99PubMedGoogle Scholar
  13. 13.
    Grieco A, Forgione A, Miele L et al (2005) Fatty liver and drugs. Eur Rev Med Pharmacol Sci 9:261–263PubMedGoogle Scholar
  14. 14.
    Hamed SA, Hamed EA, Hamdy R Nabeshima T (2007) Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 74:183–192PubMedCrossRefGoogle Scholar
  15. 15.
    Isojärvi JI, Laatikainen TJ, Knip M et al (1996) Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579–584PubMedCrossRefGoogle Scholar
  16. 16.
    Isojärvi JI, Rattya J, Myllyla VV et al (1998) Valproate, lamotrigine, and insulin mediated risks in women with epilepsy. Ann Neurol 43:446–451PubMedCrossRefGoogle Scholar
  17. 17.
    Johannessen CU, Johannessen SI (2003) Valproate: past, present, and future. CNS Drug Rev 9:199–216PubMedGoogle Scholar
  18. 18.
    Keskin M, Kurtoglu S, Kendirci M et al (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115:500–503CrossRefGoogle Scholar
  19. 19.
    Luef GJ, Abraham I, Haslinger M et al (2002) Polycystic ovaries, obesity and insulin resistence in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 249:835–841PubMedCrossRefGoogle Scholar
  20. 20.
    Luef GJ, Waldmann M, Sturm W et al (2004) Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 55:729–732PubMedCrossRefGoogle Scholar
  21. 21.
    Maheshwari A, Thuluvath PJ (2006) Cryptogenic cirrhosis and NAFLD: are they related? Am J Gastroenterol 101:664–668PubMedCrossRefGoogle Scholar
  22. 22.
    Marchesini G, Brizi M, Morselli-Labate AM et al (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–455PubMedCrossRefGoogle Scholar
  23. 23.
    Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMedCrossRefGoogle Scholar
  24. 24.
    Marshall WA, Tanner JM (1969) Variations in the pattern of pubertal changes in girls. Arch Dis Child 44:291–303PubMedCrossRefGoogle Scholar
  25. 25.
    Pylvanen V, Pakarinen A, Knip M, Isojärvi JI (2006) Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 8:643–648PubMedCrossRefGoogle Scholar
  26. 26.
    Radetti G, Kleon W, Stuefer J, Pittschieler K (2006) Nonalcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr 95:833–837PubMedCrossRefGoogle Scholar
  27. 27.
    Saadeh S, Younossi ZM, Remer EM et al (2002) The utility of the radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 123:745–750PubMedCrossRefGoogle Scholar
  28. 28.
    Sato K, Ueda Y, Ueno K et al (2005) Hepatocellular carcinoma and non-alcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 447:996–999PubMedCrossRefGoogle Scholar
  29. 29.
    Verrotti A, Basciani F, De Simone M et al (2002) Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 17:265–268PubMedCrossRefGoogle Scholar
  30. 30.
    Verrotti A, Greco R, Latini G, Chiarelli F (2005) Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Pediatr Endocrinol Metab 18:423–430PubMedGoogle Scholar
  31. 31.
    Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modelling. Diabetes Care 27:1487–1495PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Alberto Verrotti
    • 1
    Email author
  • Giovanna Di Marco
    • 1
  • Rosanna la Torre
    • 1
  • Piernicola Pelliccia
    • 1
  • Francesco Chiarelli
    • 1
  1. 1.Department of PediatricsUniversity of ChietiChietiItaly

Personalised recommendations